Prophylactic HIV drugs Market will be Massively Influenced by Macroeconomic Fact

Posted by Shirish Wadaskar on August 21st, 2019

Prophylactic HIV drugs: Market Insights

HIV is one of the leading cause of death worldwide affecting millions of people. HIV has become the chief contributor to the global burden diseases. According to World Health Organization statistics report, an estimate of around 36.9 million people are living with HIV in 2017 and 21.7 million people had received antiretroviral treatment by the end of 2017. Prophylactic HIV is a course of HIV treatment which is prescribed by physicians to prevent HIV infection in certain circumstances. It is an emergency treatment given after possible HIV exposure to prevent HIV infection. Prophylactic HIV drugs such as antiretroviral (ARV) is generally used to prevent HIV infection.

Prophylactic HIV drugs: Market Dynamics

Prophylactic HIV drugs witness to have considerable growth in the market since it reduces the chances of HIV infection. Moreover due to its cost effectiveness, there is a high demand among people for prophylactic HIV drugs. In addition to this, increasing prevalence of HIV infection and its treatment, growing government initiatives in spreading awareness among people about the HIV causes, symptom, precautions and treatment and launch of new novel drugs for the treatment is likely to drive the growth of the prophylactic HIV drugs market. However, stringent government regulation in approval and launch of drugs may restrain the growth of the prophylactic HIV drugs. Apart from this, potential side effects of the prophylactic HIV drugs may hamper the growth of the prophylactic HIV drugs market.